CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I/II Study With the Combination of Afatinib and Selumetinib in Advanced KRAS Mutant Positive and PIK3CA Wildtype Non-small Cell Lung Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02450656
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:36:49.493069+00:00
- Published At
- 2018-08-27T00:00:00+00:00
- Record Updated At
- 2018-08-27
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Colorectal Neoplasms", "Gastrointestinal Neoplasms", "Pancreatic Neoplasms", "Carcinoma, Non-Small-Cell Lung"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-08-27"- protocolSection.identificationModule.nctId
"NCT02450656"- protocolSection.identificationModule.officialTitle
"Phase I/II Study With the Combination of Afatinib and Selumetinib in Advanced KRAS Mutant Positive and PIK3CA Wildtype Non-small Cell Lung Cancer"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.